Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Abstract

A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and / or therapeutic target for cancers,. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Description

[0001] This application is a continuation of U.S. patent Ser. No. 09 / 935,430, which claims the benefit of U.S. Provisional Patent Applications 60 / 282,739, filed Apr. 10, 2001, and 60 / 227,098, filed Aug. 22, 2000. The entire contents of which are herein incorporated by reference in their entirety.SUBMISSION ON COMPACT DISC [0002] The content of the following submission on compact discs is incorporated herein by reference in its entirety: A compact disc copy of the Sequence Listing (COPY 1) (file name: 511582005003, date recorded: Nov. 15, 2004, size: 208,896 bytes); and a duplicate compact disc copy of the Sequence Listing (COPY 2) (file name: 511582005003, date recorded: Nov. 15, 2004, size: 208,896 bytes). FIELD OF THE INVENTION [0003] The invention described herein relates to a novel nucleic acid sequence and its encoded protein, referred to as 158P1D7, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7. BACK...

AI Technical Summary

Benefits of technology

[0033] The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 158P1D7 such as

Problems solved by technology

Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.

However these methods demonstrate poor sensitivity.

Although the telomeric repeat assay which measures telomerase activity is relatively sensitive, instability of telomerase in urine presently renders this detection method unreliable.

Most muscle-invasive cancers are not cured by TUR alone.

In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary are primary causes of cancer death.

Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer.

Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.

On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease.

Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.

Until recently, metastatic disease has been refractory to any systemic therapy.

Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men.

Nevertheless, there are serious side effects or sequelae to these treatments.

Rates among women have remained approximately constant but may be beginning to decline.

These treatment options can extend survival and / or relieve symptoms in many patients but are not likely to produce a cure for most.

Images